TrialCNS drugs2014

Long-term (1 year) safety and efficacy of methylphenidate modified-release long-acting formulation (MPH-LA) in adults with attention-deficit hyperactivity disorder: a 26-week, flexible-dose, open-label extension to a 40-week, double-blind, randomised, placebo-controlled core study.

Y Ginsberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.